Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting CD19 with genetically modified EBV-specific human T lymphocytes.

C Roessig1, S P Scherer, A Baer

  • 1University Children's Hospital Münster, Department of Pediatric Hematology and Oncology, Albert-Schweitzer-Str. 33, 48149 Münster, Germany.

Annals of Hematology
|March 4, 2003
PubMed
Summary

Genetically engineered Epstein-Barr virus-specific T cells target CD19-expressing B cell malignancies. These modified T cells show potential for eradicating minimal residual disease in leukemia patients post-transplant.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

A Practical Guide to 16S rRNA Microbiome Analysis in Musculoskeletal Disorders.

Methods in molecular biology (Clifton, N.J.)·2023
Same author

Evidence review of physical distancing and partition screens to reduce healthcare acquired SARS-CoV-2.

Infection prevention in practice·2021
Same author

Protecting the Microbiota.

The Journal of infectious diseases·2021
Same author

Weight of salivary gland ultrasonography compared to other items of the 2016 ACR/EULAR classification criteria for Primary Sjögren's syndrome.

Journal of internal medicine·2019
Same author

Curative Radiotherapy for Lung Cancer in the UK: International Benchmarking.

Clinical oncology (Royal College of Radiologists (Great Britain))·2019

Area of Science:

  • Immunology
  • Oncology
  • Cell Therapy

Background:

  • Epstein-Barr virus (EBV) infects B cells, contributing to certain malignancies.
  • CD19 is a cell surface marker present on most B cell malignancies.
  • Allogeneic bone marrow transplantation is a treatment for leukemia, but minimal residual disease can persist.

Purpose of the Study:

  • To genetically modify human EBV-specific T cells to express chimeric receptors targeting CD19.
  • To evaluate the efficacy and safety of these modified T cells in targeting EBV and CD19-positive tumor cells.
  • To assess their potential as an adoptive immunotherapy for leukemia patients.

Main Methods:

  • Genetic modification of human EBV-specific T cells to express chimeric antigen receptors (CARs) targeting CD19.

Related Experiment Videos

  • Expansion and maintenance of modified T cells in the presence of EBV-infected B cells.
  • Assessment of T cell recognition of autologous and allogeneic targets via T cell receptor (TCR) and CAR.
  • Evaluation of cytotoxic activity against CD19-positive tumor targets and EBV-infected cells.

    • Main Results:

    • Receptor-modified EBV-specific T cells could be expanded and maintained long-term.
    • These cells recognized autologous EBV-infected targets via TCR and allogeneic targets via CAR.
    • Efficient lysis of both EBV and CD19-positive tumor targets was observed.
    • No significant background cytotoxicity against CD19-negative targets was detected.

    Conclusions:

    • Donor-derived EBV-specific T cells engineered with chimeric anti-CD19 receptors are effective against B cell malignancies.
    • These cells demonstrate specific tumor cell lysis without off-target effects.
    • This approach offers a potential source of effector cells for eradicating minimal residual disease in leukemia patients after allogeneic bone marrow transplantation.